Peptide Decoding
New?New to peptides?Start here →
Decoding

GHK-Cu_Dosage, benefits & legal status

Also known as copper peptide, copper tripeptide-1, GHK copper

Published July 22, 2026 · Updated July 25, 2026

A copper skincare peptide for smoother, firmer, younger-looking skin.

Skin & repairCopper peptideOTC / supplement
Common vial size50 mg
DoseTopical serum, 1-2 pumps
FrequencyDaily
RouteOn the skin (also injectable, off-label)
StatusCosmetic ingredient
CycledNot cycled

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

01

What is GHK-Cu?

Plain language first. The technical label stays, but it never stands alone.

Overview

Put on the skin, it signals collagen and healing. That is why it is a popular anti-aging skincare ingredient.

The technical version

GHK-Cu is a natural copper-binding tripeptide (glycyl-histidyl-lysine plus copper) the body uses in tissue repair, and levels fall with age.

What it's used for

A skincare peptide used to smooth fine lines, fade dark spots, firm skin, and speed wound healing by boosting collagen. It is basically anti-aging for your skin.

02

How does GHK-Cu work?

What it does in the body, and where.

GHK-Cu is three amino acids bound to a copper atom. Your body makes it, levels fall sharply with age, and the copper is doing much of the work.

  1. 01
    It carries copper into skin cells
    Copper is required by the enzymes that build collagen and elastin, and this peptide is how the body delivers it.
  2. 02
    Collagen production rises
    The measurable effect in skin studies, along with faster closure of small wounds.
  3. 03
    Applied to skin, not injected, for most uses
    The cosmetic evidence is for topical use. Injected use is off-label and much less studied.
Where it acts
Skin

Where this compound is thought to act.

03

What else is it used for?

Each group carries its own evidence level.

Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Skin and wrinkles

Early research
  • Human trialOver 12 weeks, a copper-peptide serum reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% against a control serum.
  • Human trialIt reduced wrinkle volume 31.6% more than a leading peptide comparator.
  • Human trialIn 21 women measured by ultrasound, skin collagen density rose about 28% on average over three months, and near 51% in the top quarter.

Wound healing and gene activity

Research only
  • Animal studyWound-healing activity is documented across multiple animal studies.
  • Lab studyIn gene-expression analyses it shifts the activity of more than 4,000 human genes, though this is lab work rather than proof of anti-aging in people.
  • No dataThe strong safety record applies to topical use. Injectable forms do not have this evidence behind them.
Often left out

Some frequently cited recent trial figures on vendor sites could not be verified against published literature. The solid evidence is topical, not injectable.

The published record

Research index

156

Records indexed for GHK-Cu

53 in humans, 34 of them original studies.

3 registered trials, 0 with posted results.

FDA: Category 1, except injectable routes · FDA: Injectable route: nominated but withdrawn; previously category 2.

Browse the records

In animalsPro
In the labPro
ReviewsPro
Senior author sharePro

Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 11 September 2026.

GHK-Cu vial rendering
Compound field notes

At a glance

Four things to know about GHK-Cu

01

Evidence

OTC / supplement

02

Category

Skin and cosmetic

03

Common vial

50 mg

04

Half-life

Not measured for either route

04

How much, and do you cycle it?

The range, and whether you take breaks.

Topical serum, 1-2 pumps, daily. Not cycledCommunity practice

Used daily as part of a routine. The effect depends on continued use and returns to baseline when you stop, so there is nothing to cycle off.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not measured for either routeNo figure

Applied to the skin, a blood half-life is the wrong measure, since it is not meant to reach the bloodstream. Injected, no measurement has been published. Papers showing GHK levels falling with age measure what the body already contains rather than what happens after a dose.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Printed on the vial.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: Topical serum, 1-2 pumpsNo range

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

Your draw

0 / 100 units
What it costs

GHK-Cu starts at $19.49 across 77 vendors, typically $0.45 – $1.43 per mg.

177 listings, last read Sep 6, 2026. Shipping and card fees are not included.

See all 177 listings →
07

How do you store it?

Before mixing, and after.

Room temperature, out of light. Cap it tight after each use.

GHK-Cu ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.
Handling note

Stings a little going in, and that is normal. Inject slowly into a fattier area to ease it.

Who should avoid it

Check these before anything else.
  • A known copper allergy or metal sensitivity, so patch test first
  • Broken or actively irritated skin
  • Layering with strong acids or retinoids on the same area

Stop and get help

These are emergencies. Seek care.
  • A spreading rash or significant swelling where applied

Common effects

Expected, and usually mild.
  • Mild, temporary skin irritation, redness, or itching
  • Among the least irritating copper compounds in comparison studies
  • The good safety record applies to topical use. Injectable and oral forms lack this database

What regulators say

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is GHK-Cu approved?

And where the numbers on this page come from.

Not as a medicine. GHK-Cu is sold without a prescription as a supplement or cosmetic ingredient, which is a different thing from being approved as a drug.

  • Injected under the skin
    Research onlyNomination withdrawn, not permittedThe injectable form was listed in 2023 as possibly presenting significant safety risks. That nomination was withdrawn in April 2026, which ended the review rather than clearing the compound. The listing never applied to the topical form.
  • On the skin
    OTC / supplementPermitted in pharmacy compoundingTopical GHK-Cu is permitted in pharmacy compounding and is widely sold as a cosmetic ingredient.
  • Route
    On the skin (also injectable, off-label)
  • Checked
    July 2026

What has happened recently

Topical GHK-Cu is permitted in pharmacy compounding. The injectable form was listed in 2023 as possibly presenting significant safety risks, and that nomination was withdrawn in April 2026.

You can compare this against the whole library, or read how to check a seller.


Guides for this compound

Sources

  • Peer-reviewed review, tripeptides in wound healing and skin regeneration(2025)
    Peer-reviewed review of tripeptides in wound healing.
  • NIH PMC, GHK-Cu study(2025)
    Study of GHK-Cu in tissue repair.
  • GHK-Cu regeneration review, PubMed Central
  • FDA, bulk drug substances for compounding that may present significant safety risks(2026)
    FDA's entry is scoped to injectable routes only, which matters for a compound sold both as a topical and as an injection. For injectable GHK-Cu it cites immunogenicity risk from aggregation and peptide-related impurities, and says there are limited data in humans to inform safety. Nothing here speaks to topical use. As of the 22 April 2026 version of this page, the substance sits in the second table, headed bulk drug substances nominated but withdrawn, rather than in the live category 2 list. The nomination was withdrawn, which is not the same as being approved or cleared: FDA still publishes the safety language above, and no longer has a nomination in front of it to evaluate.
  • CIR Expert Panel safety assessment of Tripeptide-1, Hexapeptide-12, their metal salts and fatty acyl derivatives, and Palmitoyl Tetrapeptide-7, International Journal of Toxicology(2018)
    GHK-Cu is Copper Tripeptide-1 in cosmetic nomenclature, and this assessment concluded it is safe in cosmetics at present practices of use and concentration, which for this ingredient group means typical concentrations under 10 ppm. Two caveats belong with that. The report records that GHK itself is rapidly degraded after intravenous injection in rats and is unstable in human plasma, broken down by aminopeptidases, which is relevant to any non-topical use. And the Panel states its conclusion applies only to the named sequence, because INCI names are not sequence-specific. This is a topical cosmetic safety judgement at trace concentrations, and it speaks to neither injection nor efficacy.
  • FDA, Bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026(2026)
    The regulatory position on GHK-Cu moved twice in three weeks in 2026 and the current one turns on route. FDA removed GHK-Cu from category 1 on 22 April 2026 because the nominations for it had been withdrawn. On 5 May 2026 one of the nominators clarified that it had meant to withdraw only the injectable route, and wished to keep its nomination for non-injectable routes. So the entry now reads GHK-Cu except for injectable routes of administration, restored to category 1. FDA has also said it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should go on the 503A bulks list at all. The practical reading for someone choosing between a serum and a vial: the version of GHK-Cu that nobody is currently asking FDA to permit in compounded medicines is the injectable one.

Last reviewed 22 July 2026

Beyond these, 156 records are indexed. Browse the records